Is FXI inhibition the future of the management of cancer-associated thrombosis?

Dr. Marcello Di Nisio provided an elegant review ICTHIC
Potentially low risk of bleeding, less drug-drug interactions, less dependence on renal/liver for elimination.
Phase 3 trials on-going! Stay

From veins to brains: Shifting paradigm in Cancer Associated Thrombosis.

Strokes are common just before or right after cancer diagnosis. Cancer types, prior history of stroke and tumor stage are important predictors of CVA. More studies are needed. #ICTHIC2024

Congratulations Marc Carrier for this well-deserved recognition as an exemplary mentor to so many of us ISTH

Infection-induced inflammation impairs wound healing through IL-1β signaling cell.com/iscience/fullt…
Exp model, IL-1 blockade with anakinra favors wound healing without impairing pathogen clearance. Stefano Toldo Nicola Potere Benjamin Van Tassell Brittany Weber Dr. Michael Garshick Marco Del Buono

🩸 How to manage #anticoagulation in patients with isolated distal deep vein #thrombosis ?

📖 Clinical Focus from Nicola Potere et al. ⤵️

👉 thieme-connect.com/products/ejour…

#DVT #VTE #cvCoag #hematology

Laura Parma daniele.pastori José Miguel Rivera Giulio Francesco Romiti

#Inflammation 🔄 #coagulation crosstalk during #infection 🦠 incl acute/long #COVID19 , and promising therapeutics💊 targeting #immunothrombosis 🔥🩸

Splendid cover art European Society of Cardiology Journals
👉 academic.oup.com/cardiovascres/…

#JACCBTS state-of-the-art review provides an overview of preclinical and clinical evidence supporting IL-1 and the NLRP3 inflammasome as potential therapeutic targets in #VTE : bit.ly/45qTx5Z

#CardioTwitter Nicola Potere Yogen Kanthi Marc Carrier Marcello Di Nisio

Incredible piece in JACC Journals by some of the best in clinical trials on incorporating recurrent events

Absolutely worth reading for those in research and clinicians alike!

jacc.org/doi/10.1016/j.…

Anticoagulants did not reduce ATE risk among ambulatory pts on systemic anticancer therapy & were assoc w/ increased bleeding. Based on current data, anticoagulants have a limited role in ATE prevention in this population as a whole. bit.ly/3RqOOhn #JACCCardioOnc #cvCoag

Wasn’t expecting this news this morning 👀

businesswire.com/news/home/2023…

Absolutely fascinating JAMA paper this week suggesting that Cerebral Amyloid Angiopathy may actually be infectious. (Thread)

Very proud of this work - once again excessive, unresolving, inflammation is the villain!!! We have witnessed a paradigm shift in COVID-19, from avoidance of anti-inflammatory drugs to central role of immunomodulatory drugs. Power of science, basic-translational-clinical.

New 2023 ACR/EULAR Antiphospholipid Syndrome (APS) Classification Criteria are out!
Patients need at least 3 points each from the clinical and lab domains (See below) to be classified as having APS. This will be very useful to clinicians :)
acrjournals.onlinelibrary.wiley.com/doi/full/10.10…
ISTH

Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) nej.md/3PaUOJz

#ESCCongress #cardiology

#ESC2023 #ESCCongress . Spotlight on ONCO #DVT study - highly informative/needed data on the optimal duration of #anticoagulation for #cancer -associated isolated distal deep vein #thrombosis (IDDVT)

👉mp.pl/paim/issue/art…

Excellent work led by the one-and-only Nicola Potere UVA CVRC UVA Cardio

Patients with cancer and COVID-19 need close monitoring for thromboembolism and consideration for risk-mitigating thromboprophylaxis, especially if recently exposed to systemic anticancer drugs. ja.ma/3QFCglF

The #MACT pilot study shows combining #P2Y12 inhibitor monotherapy (ticagrelor/prasugrel) w/ colchicine post- #PCI in #ACS pts results in favorable platelet reactivity, & slashes high #CRP / inflammation by a whopping 70%. bit.ly/3KGiIty

#JACCINT #cvACS #CardioTwitter

Dear colleagues, friends, and all fans of thromboinflammation and platelets, please see our paper on the topic, that came out today: frontiersin.org/articles/10.33…

Presented at #IAS2023 : In a trial involving participants with HIV infection receiving antiretroviral therapy, the use of pitavastatin resulted in a lower risk of a major adverse cardiac event than placebo at a median of 5.1 years. Read the full REPRIEVE trial results: